SIGN IN YOUR ACCOUNT TO HAVE ACCESS TO DIFFERENT FEATURES

FORGOT YOUR PASSWORD?

FORGOT YOUR DETAILS?

AAH, WAIT, I REMEMBER NOW!
+1 786 238 2170

Global Stem Cells GroupGlobal Stem Cells Group

  • Home
  • Our Story
  • Speakers
  • Investors
  • Companies
  • Press Releases
  • Blog
CONTACT
  • Home
  • Articles posted by AlexNovas
  • Page 27
January 31, 2026

Author: AlexNovas

Alfredo Hoyos, M.D.

Wednesday, August 24, 2016 by AlexNovas
ISSCA Hoyos

Alfredo Hoyos, M.D., Global Stem Cells Group’s chief scientific officer (CSO), is a renowned  board-certified plastic surgeon from Bogotá, Colombia. Dr. Hoyos earned his medical degree at El Rosario University in Bogotá and performed his residency in plastic surgery at the Rosario – Saint Joseph Hospital, also in Bogotá.
The inventor of High Definition Liposculpture (HDL), Dynamic Definition Lipoplasty (4D), and other advanced body contouring techniques, Dr. Hoyos has been an innovator since early in his career, embracing the potential of stem cells early on. He is well known for his surgical skills, and recognizing new opportunities to advance the efficacy of health care treatments. One of the most promising breakthroughs toward that end is the acceleration of stem cell discoveries over the past 20 years.
Dr. Hoyos recognized the potential of these remarkable, undifferentiated cells, capable of  self-reinvention when called upon to take on the functions of other cells in the body when needed, giving rise to a new field of vision for the future of surgical and aesthetic protocols, and the future of medicine altogether. Dr. Hoyos adapts the healing  and restorative capabilities of stem cells  to the aesthetic procedures he performs—including fat grafting and fat transfer—and  has successfully performed assisted stem cell fat transfer procedures for patients looking to restore volume in the facial area that is lost in the natural aging process.
Dr. Hoyos continues to identify new opportunities in innovative medical technology that can improve the quality of patients’ lives.  After adopting and mastering  Vaser ultrasonic liposuction technology, also known as liposelection (an alternative to traditional liposuction) he later developed the Vaser Hi Definition Lipoplasty (VHD) procedure.
Dr. Hoyos founded Stem Lab, a biotechnology company based in Bogotá, to further the development of stromal stem cells derived from adipose tissue. He continues to develop and refine these techniques, while exploring new applications for HD and other emerging technologies  in the field of aesthetic  surgery.
He is an accomplished sculptor, painter, medical book illustrator and author. of several books focusing on high definition body sculpting and advanced lipoplasty techniques. Dr. Hoyos is certified by the Colombian Society of Plastic Surgery, (SCCP) and the  International Confederation of Plastic Reconstructive and Aesthetic Surgery (IPRAS).

Read more
  • Published in Advisory Board Members
No Comments

Global Stem Cells Group Announces Stem Cell Training in Madrid

Tuesday, August 16, 2016 by AlexNovas
Stem cell training Madrid
[su_spacer size=”40″]  Global Stem Cells Group has announced a stem cell training course in Madrid, Spain, to be held Dec. 6 – 7, 2016, in collaboration with Javier Garcia Alonso, MD and Clinica Castellana Norte.
[su_spacer]
stem cell training Madrid

Physicians at a recent stem cell training course

MIAMI, Aug. 16, 2016—Global Stem Cells Group and Stem Cell Training, Inc. will host a stem cell training course in Madrid, Dec. 6-7, 2016, in collaboration with Javier Garcia Alonso, MD of Clinica Castellana Norte in Madrid. Garcia Alonso is a specialist in plastic, reconstructive and aesthetic surgery.

The stem cell training course, available to qualified physicians, will focus on stem cell protocols in cosmetic, anti-aging, and aesthetic procedures.

The Adipose and Bone Marrow Stem Cell Training Course was developed for physicians and high-level practitioners to learn the process through a two-day, intensive, hands-on training program to arm participating physicians with clinical protocols and state-of-the-art techniques for isolating and re-integrating adipose- and bone marrow-derived stem cells. When used in aesthetic medicine therapies, patients walk away with more natural-appearing augmentation and enjoy a faster recovery period with little to no downtime.

Garcia Alonso will host and participate in training qualified physicians in stem cell harvesting, isolating and re-integration stem cell training course in Barcelonatechniques and protocols, during which stem cells are harvested from the patient’s own body and redistributed to areas of the body receiving augmentation.

Stem cell therapy is a promising treatment for facial rejuvenation and soft tissue augmentation because there are no incisional scars or complications associated with foreign materials. Demand for stem cell procedures s high worldwide—these effective procedures that do not involve going under the knife are driving the growth of stem cell protocols in the cosmetic industry, as more patients request new technologies that are less invasive than ever before.

Breast augmentatistem cell training course in Barcelonaon, abdominoplasty, facelifts and liposuction continue to feature in the top most requested procedures for many clinics, surgeons say an increasing number of patients are seeking a more natural look with a quicker recovery time, according to Benito Novas, CEO of Global Stem Cells Group. In fact, non-surgical cosmetic procedures have grown exponentially over the past five years, and the trend is expected to continue to rise.

Surgeons are also seeing more diverClinica Castellana Norte.sity when it comes to the type of procedures requested, including buttock enhancements, hair transplantation and anti-aging procedures on hands.

“Patients are demanding procedures that are quick, easy, and provide a fast recovery with minimal downtime,” Novas says. “Stem cells provide the ability to rejuvenate and heal, making them a natural treatment for cosmetic and anti-aging applications.”

The stem cell training course will be offered through Global Stem Cells Group affiliate Stem Cell Training, Inc.

To learn more, visit the Global Stem Cells Group website, or the Stem Cell Training website, email bnovas(at)regenestem(dot)com, or call +1 305 560 5337.

About Global Stem Cell Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

About Stem Cell Training, Inc.:

Stem Cell Training, Inc. is a multi-disciplinary company offering coursework and training in 35 cities worldwide. The coursework offered focuses on minimally invasive techniques for harvesting stem cells from adipose tissue, bone marrow and platelet-rich plasma. By equipping physicians with these techniques, the goal is to enable them to return to their practices, better able to apply these techniques in patient treatments.

About Clinica Castellana Norte:

Clinica Castellana Norte in Madrid of
fers a comprehensive range of aesthetic and reconstructive procedures, from dietary advice to state-of-the-art stem cell therapies for cosmetic procedures. Clinica Castellana Norte operates under the highest quality standards, not only in medical and aesthetic treatments offered, but throughout the administrative process, ensuring privacy. Clinica Director Javier Garcia Alonso, M.D., is a member of the Spanish Society of Plastic Reconstructive and Aesthetic Surgery (SECPRE), and a member of the International Society of Plastic, Reconstructive and Aesthetic Surgery (IPRAS).

To view this press release live online, click here

###

regenerative medicineSTEM CELL TRAININGstem cell training in madridstem cells
Read more
  • Published in Press Releases
No Comments

Global Stem Cells Group to Honor Joseph Purita, MD at 3rd Annual International Symposium on Stem Cells and Regenerative Medicine in Buenos Aires

Tuesday, August 16, 2016 by AlexNovas
Buenos Airies stem cell symposium
[su_spacer size=”50″]  
Global Stem Cells Group will honor Joseph Purita, MD at its 3rd Annual International Symposium on Stem Cells and Regenerative Medicine, to be held in Buenos Aires Sept. 28, 2016. Purita, an active contributor to the Miami-based biotech company, has been a key participant in GSCG’s growth since it launched in 2013.
[su_spacer size=”20″]
Joseph Purita MD

Joseph Purita, MD

MIAMI, Aug. 16, 2016—Global Stem Cells Group plans to honor Joseph Purita, MD, during its 3rd Annual International Symposium on Stem Cells and Regenerative Medicine, to be held in Buenos Aires, Argentina Sept. 28, 2016. The symposium will be hosted in collaboration with Julio Ferreira, MD, President of the South American Academy Cosmetic Surgery, an event expected to attract a record number of physicians, researchers and regenerative medicine experts from around the world.
Julio Ferreira advisory board, Global Stem Cells Group

Julio Ferreira, MD

Purita, a renown orthopedic and arthroscopic surgeon heads GSCG’s Scientific Advisory Board. A pioneer in the use of Stem Cell and PRP therapy for orthopedic conditions, Purita has practiced with the Boca Raton Orthopaedic Group in Boca Raton, Florida since 1981. In 2012, Purita gained international attention when he treated New York Yankees pitcher Bartolo Colon’s ligament damage with stem cells, restoring the athlete’s injured shoulder and career. Purita has since treated an array of professional athletes with career-threatening injuries.

The GSCG Symposium offers an opportunity for many of the world’s most respected authorities on stem cell and regenerative medicine to join Purita and other industry leaders to showcase advancements in research and therapies on a global level.

Duncan Ross, PhD

Duncan Ross, PhD

An interdisciplinary team of stem cell experts will provide a full day of high-level scientific lectures geared to medical professionals. Pioneers and luminaries in stem cell medicine will serve as featured speakers, led by keynote speakers Purita and Duncan Ross, PhD Ross, a GSCG Advisory Board faculty member, is a molecular biologist, immunologist and researcher, and the founder of Kimera Labs.

According to Benito Novas, Global Stem Cells Group CEO, the world-class event will showcase the historic advances in stem cell medicine achieved since the first symposium was held just two years ago in 2014.

“We’ve come so far since 2014, and this year’s symposium will highlight the strides Global Stem Cells Group has made in these two years,” Novas says. “And it is only fitting that we take the opportunity to acknowledge Dr. Purita’s contributions to our growth.

“This year, we will showcase how far stem cell therapies have come, and provide some of the most influential leaders like Dr. Purita, who understand the potential of these therapies and have dedicated their careers to making them a reality.”

Since 2014, Global Stem Cells Group has joined forces with some of the most prestigious regenerative medicine practitioners in South America as it focuses on growing its services throughout the global community. Stem cell therapies continue to revolutionize the anti-aging aesthetics industry while offering new hope for sufferers of serious chronic debilitating diseases.

To learn more about the 3rd Annual International Symposium on Stem Cells and Regenerative Medicine, visit the Global Stem Cells Group website, email bnovas(at)regenestem(dot)com, or call 305-560-5337.

About Global Stem Cells Group:

stem cell training course in BarcelonaGlobal Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

About Joseph Purita, MD

Joseph Purita, MD, a pioneer in the use of Stem Cell and PRP therapy for orthopedic conditions, graduated from Georgetown University Medical School and served his surgical internship at the University of Florida Medical Center. Following completion of a residency in orthopedic surgery at University of Miami-Jackson Memorial Hospital, where he served as chief administrative resident, Dr. Purita joined the Boca Raton Orthopaedic Group in 1981.

Purita is a Fellow, American Academy of Orthopedic Surgeons; Fellow, American College of Surgeons; member, American Medical Association; member, Southern Medical Association; member, Palm Beach Medical Society; member, Broward County Medical Society; member, Palm Beach Orthopedic Society, and member, Florida Medical Association. His certifications include the American Board of Orthopedic Surgery; American College of Orthopaedic Surgery; American Board of Pain Management, and the American Board of Regenerative Medicine.

Purita is an instructor and proctor of surgeons in the use of lasers in arthroscopic and orthopedic surgery at a variety of area hospitals, and heads GSCG’s Scientific Advisory Board.

To view this press release live online, click here

###

Buenos Aires SymposiumJoseph Purita MDregenerative medicinestem cells
Read more
  • Published in Press Releases
No Comments

Julio Ferreira, M.D.

Monday, August 15, 2016 by AlexNovas
Julio Ferreira advisory board, Global Stem Cells Group

Julio Ferreira, M.D.
Global Stem Cells Group Advisory Board member

Julio Ferreira, M.D., is an internationally recognized and respected cosmetic surgeon and professor of medicine and aesthetic surgery at the Institute of Biomedical Sciences, University of Sao Paulo, Brazil;
As director of Clinica Ferreira in Argentina, Dr. Ferreira is dedicated to the combination of art and science in aesthetic medicine.
Dr. Ferreira serves as president of the South American Academy of Cosmetic Surgery and expert examiner at the International Board of Cosmetic Surgery. He also serves on the International Editorial Advisory Board of the American Journal of Cosmetic Surgery; former President of the International Academy of Cosmetic Surgery 2005/2007; a member and examiner, International Board of Cosmetic Surgery; Corresponding Fellow of the American Academy of Cosmetic Surgery; Honorary Member of the Spanish Society of Cosmetic Medicine and Surgery; Honorary Member of the Eurorusa Confederation of Societies of Aesthetic Plastic Surgery; Honorary Member of the Bulgarian Society of Cosmetic Surgery; Honorary Member of the Chilean Society of Cosmetic Surgery and Lipoplasty; Honorary Member of the Italian Society of Aesthetic Surgery, and Honorary Member of the French Society of Aesthetic Surgery.
 

global stem cells groupregenerative medicinestem cells
Read more
  • Published in Advisory Board Members
No Comments

Joseph Purita, M.D.

Monday, August 15, 2016 by AlexNovas
Buenos Aires Stem Cell Symposium

Joseph Purita, M.D.
Global Stem Cells Group Advisory Board member


Joseph Purita, M.D., is a world-renowned orthopedic surgeon and stem cell pioneer, using cutting edge technology in regenerative medicine in conjunction with stem cell platelet rich plasma (PRP) therapy to treat orthopedic injuries and relieve pain. He is also a pioneer in the use of the laser in orthopedic surgery.
Named a U.S. News and World Report Top Doctor in 2012, Dr. Purita, a renown orthopedic and arthroscopic surgeon, heads Global Stem Cells Group’s Scientific Advisory Board. A pioneer in the use of stem cell and PRP therapy for orthopedic conditions, Dr. Purita has practiced with the Boca Raton Orthopaedic Group in Boca Raton, Florida since 1981. In 2012, Purita gained international attention when he treated New York Yankees pitcher Bartolo Colon’s ligament damage with stem cells, restoring the athlete’s injured shoulder and career. Purita has since treated an array of professional athletes with career-threatening injuries.
Dr. Purita is the director of the Institute of Regenerative and Molecular Orthopedics in Boca Raton, Florida, specializing in the use of stem cells and PRP injections for use in sports medicine and other musculoskeletal conditions. The Institute has treated some of the most prominent professional athletes from all major sports in both the U.S.. and abroad.
He is an instructor and proctor of surgeons in the use of lasers in arthroscopic and orthopedic surgery at a variety of area hospitals,
Dr. Purita is a Fellow, American Academy of Orthopedic Surgeons; Fellow, American College of Surgeons; member, American Medical Association; member, Southern Medical Association; member, Palm Beach Medical Society; member, Broward County Medical Society; member, Palm Beach Orthopedic Society, and member, Florida Medical Association. His certifications include the American Board of Orthopedic Surgery; American College of Orthopaedic Surgery; American Board of Pain Management, and the American Board of Regenerative Medicine.
He is Is Board Certified By The Following Organizations:
•  American Board of Orthopedic Surgery
•  American College of Orthopaedic Surgery
•  American Board of Pain Management
Dr. Purita is a popular speaker at regenerative and orthopedic conferences worldwide.
 

 
 
 
 

Global stem cells group advisory boardregenerative medicinestem cell medicinestem cells
Read more
  • Published in Advisory Board Members
11 Comments

Global Stem Cells Group Announces Stem Cell Training Course Scheduled in Barcelona

Wednesday, August 10, 2016 by AlexNovas
stem cell training course in Barcelona

Global Stem Cells Group and its subsidiary Stem Cell Training, Inc., have announced plans to hold a stem cell training course in Barcelona, Spain, Nov. 11 – 12, 2016. Orthopedic and cosmetic surgeon J. Victor Garcia Gimenez, M.D. will conduct the course for qualified physicians and medical professionals.
[su_spacer]

stem cell training course in Barcelona

J. Victor Garcia Gimenez, M.D.

MIAMI, Aug. 10, 2016–Global Stem Cells Group and its subsidiary Stem Cell Training, Inc. will host a stem cell training course in Barcelona, Spain, Nov. 11 – 12, 2016. Victor Garcia Gimenez, M.D. will conduct the two-day, intensive, hands-on “Adipose-derived Harvesting, Isolation and Re-integration Training Course” for physicians and qualified medical professionals.

Garcia Gimenez, a member of the Global Stem Cells Group Advisory Board, first conducted the course for GSCG in 2014. The

course is part of the Miami-based biotech company’s growth in the European market.

The training course was developed for physicians and high-level practitioners to learn clinical protocols and state-of-the-art techniques for isolating and re-integrating adipose- and bone marrow-derived stem cells. Stem cells are harvested from the patient’s own body and redistributed to areas of the body receiving treatment. Patients experience an effective, non-invasive procedure, and a faster recovery period with little to no downtime.

Garcia Gimenez is a specialist in orthopedic and cosmetic surgery, president of Therapeutic Confrontations (CONFTERA), and practices cosmetic and anti-aging medicine, as well as aesthetic therapies in Barcelona. He is the president of the Spanish Society of Medicine and Cosmetic Surgery; co-director of the UAB-SEMCC; Chairman for Spain of the International Academy of Cosmetic Surgery, in addition to other medical and professional boards.

The stem cell training course will be offered through Global Stem Cells Group affiliate Stem Cell Training, Inc.

To learn more, visit the Global Stem Cells Group website, or the Stem Cell Training website, email bnovas(at)regenestem(dot)com, or call +1 305 560 5337.

About Global Stem Cell Group:stem cell training course in Barcelona

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

About Stem Cell Training, Inc.:

stem cell training course in BarcelonaStem Cell Training, Inc. is a multi-disciplinary company offering coursework and training in 35 cities worldwide. The coursework offered focuses on minimally invasive techniques for harvesting stem cells from adipose tissue, bone marrow and platelet-rich plasma. By equipping physicians with these techniques, the goal is to enable them to return to their practices, better able to apply these techniques in patient treatment.

To view this press release live online, click here.

###

medical tourismregenerative medicinestem cell educationSTEM CELL TRAINING
Read more
  • Published in Press Releases
No Comments

Texas Man Becomes First Adult in the U.S. to Receive Updated Stem Cell Transplant to Treat Leukemia

Tuesday, August 9, 2016 by AlexNovas
stem cell transplant

Introduction to the Groundbreaking Stem Cell Transplant

Chuck Dandridge, a Mansfield, Texas resident, became the first adult in the U.S. to receive a newly modified stem cell transplant that uses genetically engineered blood cells from a family member. The milestone was announced by researchers at UT Southwestern Medical Center’s Harold C. Simmons Comprehensive Cancer Center in Dallas, where the procedure was performed.

Dandridge’s Medical Journey and Diagnosis

Dandridge’s medical journey began in 2013, with a routine doctor’s visit to check his cholesterol levels; lab tests revealed low blood counts and further testing confirmed Dandridge’s diagnosis of myelodysplastic syndrome, also called pre-leukemia or MDS. By 2014, the leukemia had progressed to acute myeloid leukemia (AML), which, according to the National Cancer Institute, affects more than 20,000 Americans annually.

Genetic Testing and Clinical Trials

Texas Man Becomes First Adult in the U.S. to Receive Updated Stem Cell Transplant to Treat Leukemia

Dandridge was referred to UT Southwestern’s Simmons Cancer Center, where his leukemia was tested for genetic mutations.
“We wanted to know whether he had specific mutations in his cancer cells,” says Madhuri Vusirikala, M.D., Professor of Internal Medicine and the primary investigator of many UT Southwestern clinical trials related to bone marrow transplantation. “We found a mutation called IDH 2, which causes the body to produce an abnormal protein that promotes excessive cell growth. If you can target that mutation and stop the abnormal protein from being produced, then cells start behaving normally.”

Participation in the AG-221 Clinical Trial

Dandridge enrolled in a UT Southwestern clinical trial for a therapy called AG-221. He took four pills each morning for the next eight months. During that time, Dandridge saw marked improvement although he did not go into complete remission, according to Vusirikala. That success made him eligible for a potentially curative stem cell transplant. But finding a donor proved challenging.

Challenges in Finding a Suitable Donor

“The best chance of finding a full match is usually a full sibling; however, Chuck has no full siblings,” Vusirikala says. Additionally, Dandridge is African American, and minorities are under-represented in the National Marrow Donor Registry—about 70 percent of registry donors are Caucasian. The search for an unrelated donor was unsuccessful. Vusirikala says that he knew Dandridge’s daughter and his son would be at least a half match. Since using a same-sex donor is preferred, as it reduces the risk of complications, his son Jon, 31, emerged as the best choice. But the risk of graft-versus-host-disease (GvHD) following a transplant using a half-match is very high, so they needed a better way to deal with the GvHD risk.

Innovative BP-001 Clinical Trial

Texas Man Becomes First Adult in the U.S. to Receive Updated Stem Cell Transplant to Treat Leukemia

Once again, Mr. Dandridge volunteered for a cutting-edge clinical trial, known as BP-001, which processed the stem cells used in the transplant to reduce the risk of rejection and engineered blood cells that can be targeted if GvHD develops after the transplant. The processes being tested in BP-001 are in clinical development by Houston-based Bellicum Pharmaceuticals. The study is evaluating patients with blood cell cancers who have a peripheral blood stem cell transplant from a partially matched relative. Immune cells (T cells) from the related donor are separated from the rest of the stem cells and genetically engineered in the Bellicum laboratory, and then given to the patient along with the stem cell transplant.

Procedure and Outcome of the Transplant

These engineered T cells are modified to include a suicide gene with the help of a retrovirus. If the patient develops GvHD after transplant, the side-effect can be treated by giving a drug called rimiducid to activate the suicide gene and cause the activated GvHD-causing cells to be eliminated. The stem cells given for the transplant were also processed prior to giving them back to Dandridge to reduce the risk of graft rejection as well as GvHD. The genetically engineered blood cells were transplanted from Dandrige’s son, Jon, 31, to the father in three, two-hour infusions at William P. Clements Jr. University Hospital in July 2015, and today the elder Mr. Dandridge’s leukemia is in remission. His immune system is recovering, and the former Norman, Oklahoma YMCA CEO is now mentoring first-time CEOs for the YMCA.

acute myeloid leukemia (AML)stem cell leukemia treatmentstem cell researchstem cell transplant
Read more
  • Published in Corporate News / Blog
No Comments

Insulin-producing Stem Cells Grown in the Lab Mark a New Era in Stem Cell Therapies for Diabetes

Monday, August 8, 2016 by AlexNovas
insulin-producing pancreatic beta cells

Introduction to Insulin-Producing Pancreatic Beta Cells

A new discovery by researchers on how to activate lab-grown beta cells to mature into functioning cells that produce and release insulin in response to glucose takes a significant step toward a cell therapy treatment for diabetes. Difficulties in manipulating beta cells derived from human stem cells to mature beyond the precursor stage into fully functioning insulin releasers have been an ongoing challenge for researchers.

Breakthrough by Salk Institute Researchers

However, researchers from the Salk Institute for Biological Studies and a team of researchers have achieved this goal with lab-grown beta cells by activating a protein called estrogen-related receptor γ (ERRγ). Their study findings were recently published in the journal Cell Metabolism.

The Role of Human Pluripotent Stem Cells (hPSCs)

Insulin-producing Stem Cells Grown in the Lab Mark a New Era in Stem Cell Therapies for Diabetes

Ronald Evans, senior author of the study titled, “ERRγ Is Required for the Metabolic Maturation of Therapeutically Functional Glucose-Responsive β Cells,” explains the self-renewing capacity of human pluripotent stem cells (hPSCs) and their ability to differentiate into most cell types—from neurons to skin cells, to muscle cells, and insulin-producing pancreatic beta cells—has inspired many research teams to find ways to make glucose-responsive beta cells in the lab. Evans and his research team discovered the answer to the insulin-releasing cell conundrum, and summed it up thusly: “In a dish, with this one switch, it’s possible to produce a functional human beta cell that’s responding almost as well as the natural thing.”

Challenges in Lab-Grown Pancreatic Beta Cells

Evans, a molecular biologist at the Salk Institute, says that to create the different types of cells in the lab, researchers coax the pluripotent stem cells (hPSCs) down the various branching paths that fetal cells normally travel in order to differentiate into the various cell types. However, he explains there are many developmental points in this process, and in the case of lab-grown pancreatic beta cells, research kept getting stuck at an early stage.

Role of ERRγ in Adult Beta Cells

In order to determine what might trigger the next step in getting the cells to mature, the researchers compared transcriptomes of adult and fetal beta cells. The transcriptome contains, among other things, the full catalog of molecules that switch genes on and off in the genome, which led them to discover that the nuclear receptor protein ERRγ was more abundant in adult beta cells. The team was already familiar with the protein’s role in muscle cells and had studied its ability to enhance endurance running. Evans says that in muscles, the protein promotes greater growth of mitochondria—the power generators inside cells that accelerate the burning of sugars and fats to make energy.

Surprising Findings on Beta Cells

“It was a little bit of a surprise to see that beta cells produce a high level of this regulator,” Evans says. “But beta cells have to release massive amounts of insulin quickly to control sugar levels. It’s a very energy-intensive process.” The research team then decided to run some tests to look more closely at what role ERRγ might play in insulin-producing beta cells.

A New Era in Creating Functional, Insulin-Producing Beta Cells

Insulin-producing Stem Cells Grown in the Lab Mark a New Era in Stem Cell Therapies for Diabetes

After they genetically engineered a deficiency of ERRγ in mice, the researchers found the animals’ beta cells did not produce insulin in response to spikes in blood sugar. Next, they tried to get beta cells made from hPSCs to produce more ERRγ, and it worked! The cells in culture began to respond to glucose and release insulin. Finally, the team transplanted the lab-grown insulin-producing beta cells into diabetic mice and found that from day one, the cells produced insulin in response to glucose spikes in the animals’ blood.

Future Implications and Research

Evans and the research team were justifiably excited by the results. It appears that just switching on the ERRγ protein is sufficient to get the lab-grown beta cells to mature and produce insulin in response to glucose – both in cultures and in live animals. Speculating on the implications of their findings, Evans suggests that when a fetus is developing, because it gets a steady supply of glucose from the mother, it does not need to produce insulin to regulate its blood sugar, so the switch is inactive. But, when the baby is born and takes its first breath and takes in oxygen, this activates the switch. Previous lab attempts to produce beta cells got stuck at the fetal stage. The Salk Institute researchers discovered how to take it to the adult stage, using the same protein that is switched on in nature.

Conclusion

“I believe this work transitions us to a new era in creating functional beta cells at will,” Evans says. He and his research team now plan to examine how the switch might work in more complex models of diabetes treatments. The Salk Institute study precedes another study reported by Medical News Today in which researchers generated mini-stomachs that produce insulin when transplanted into mice.

diabetesinsulin-producing stem cellsstem cell therapystem cells
Read more
  • Published in Corporate News / Blog
No Comments

Amazing Stem Cell Research Breakthroughs You Never Heard of

Friday, August 5, 2016 by AlexNovas
skin stem cell research

Introduction to Skin Stem Cell Research

Stem cell research has uncovered numerous groundbreaking discoveries over the years, many of which remain relatively unknown. This article highlights one such discovery related to skin stem cells and their critical role in regeneration and maintenance.

Discovery of Dnmt3a and Dnmt3b Proteins

Amazing Stem Cell Research Breakthroughs You Never Heard of
S

In a significant 2008 study published in “Cell Stem Cell,” researchers from the Catalan Institution for Research and Advanced Studies (CREA) identified two proteins—Dnmt3a and Dnmt3b—that play a crucial role in maintaining skin stem cells. Led by Salvador Aznar Benitah at the Institute for Research in Biomedicine (IRB Barcelona), the study revealed that these proteins are essential for the activation and preservation of skin stem cells.

Function of Dnmt3a and Dnmt3b in Skin Stem Cells

Amazing Stem Cell Research Breakthroughs You Never Heard of

According to Benitah, head of the Stem Cells and Cancer lab at IRB Barcelona, without Dnmt3a and Dnmt3b, skin stem cells fail to activate and eventually diminish within the tissue. The proteins operate primarily on gene enhancers and super-enhancers, facilitating the expression of approximately 1,000 genes critical for the self-renewal of skin stem cells.

Genomic Insights and Mechanisms

Lorenzo Rinaldi, a researcher involved in the study, utilized advanced sequencing techniques to map the genomic distribution of Dnmt3a and Dnmt3b. This revealed their unexpected role in enhancing gene expression through DNA methylation, contrary to their previously known function in gene repression.

Link to Cancer Research

The study also highlighted implications for cancer research, noting that Dnmt3a and Dnmt3b are altered in various types of tumors, including leukemia, lung cancer, and colon cancer. The proteins’ role in DNA methylation and gene regulation suggests potential contributions to tumor development, warranting further investigation in cancer cell models.

Funding and Support

Funded by the Spanish Ministry of Economy and Competitiveness and supported by several foundations and councils, including The European Council for Research (ERC) and the Fundació Marató de TV3, Benitah’s research underscores the importance of public and private partnerships in advancing stem cell and cancer research.

Conclusion

This study represents a significant advancement in understanding the molecular mechanisms governing skin stem cell maintenance and its implications for both regenerative medicine and cancer biology. Continued research into Dnmt3a and Dnmt3b promises to unveil new therapeutic strategies and insights into cellular regeneration and disease progression.

Dnmt3a and Dnmt3bskin stem cellsstem cell research
Read more
  • Published in Corporate News / Blog
No Comments

Global Stem Cells Group Announces Training Course Scheduled in Manila, Philippines

Tuesday, August 2, 2016 by AlexNovas
STEM CELL TRAINING COURSE

Global Stem Cells Group has scheduled the first stem cell training course to be held in the Philippines Oct. 14-15, 2016. The course will be available to physicians from the Philippines, Thailand and Singapore who are qualified for training in the latest stem cell therapies.

MIAMI, Aug. 2, 2016—Global Stem Cells Group, a world leader in regenerative medicine, has announced the first stem cell training course to be held in Manila,

stem cell training course

Makata, Manilla, Philippines

Philippines has been scheduled for Oct. 14 – 15, 2016. The course is part of a collaborative agreement between GSCG and Manila-based Eric Yalung, M.D., to train qualified physicians from the Philippines, Thailand and Singapore in the latest adipose and bone marrow therapies. The announcement signals GSCG’s renewed focus on the South East Asia markets, including permanent stem cell training centers in the Philippines and South Korea.

Adipose and Bone Marrow Stem Cell Training Course

The two-day intensive “Adipose and Bone Marrow Training Course” program will be held for referred physicians. In addition, Global Stem Cells Group will host training for its graduate course, “Diplomat in Stem Cell Training and Tissue Engineering,” with dates to be announced.

According to Global Stem Cells Group CEO Benito Novas, the agreement is the latest in the international biotech company’s ongoing expansion efforts to bring stem cell treatments to communities worldwide.

For more information, visit the Global Stem Cells Group website, email bnovas(at)stemcellsgroup (dot)com, or call (305) 560-5337.

About Global Stem Cell Group:

Global Stem Cells Groupstem cell training course is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

About Stem Cells Training:

Stem Cell Training, Inc. is a multi-disciplinary company offering coursework and training in 35 cities worldwide. Coursework stem cell training courseoffered focuses on minimally invasive techniques for harvesting stem cells from adipose tissue, bone marrow and platelet-rich plasma. By equipping physicians with these techniques, the goal is to enable them to return to their practices, better able to apply these techniques in patient treatments.

The company’s training courses are designed to make the best use of stem cell technology available to treat various diseases in a manner that is accessible to everyone. Stem Cell Training, Inc.’s mission is to introduce the promising world of cellular medicine to everyone who can benefit from its application, and to provide high quality, effective and efficient training that complies with the highest medical standards to physicians worldwide.

To view this press release live online, click here

###

STEM CELL COURSESSTEM CELL TRAININGSTEM CELL TRAINING PHILIPPINES
Read more
  • Published in Press Releases
No Comments
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30

Send Us a Message

Contact Home GSCG website

Name(Required)
Email(Required)
Please let us know what's on your mind. Have a question for us? Ask away.
  • Home
  • Our Story
  • Speakers
  • Investors
  • Companies
  • Testimonials
  • Press Releases
  • Blog

Copyright © 2024 Stem Cells Group | All Rights Reserved

CONTACT US

Datran Center 9100 S Dadeland Boulevard, Suite 1500. Miami Fl. 33156 United States

305-560-5337

info@stemcellsgroup.com

STAY CONNECTED

Get the latest news, updates, and promotions. Follow us on our social networks.

Certification issued by ISSCA

  • Home
  • Our Story
  • Speakers
  • Investors
  • Companies
  • Testimonials
  • Press Releases
  • Blog

Copyright © 2024 Stem Cells Group | All Rights Reserved

CONTACT US

Datran Center 9100 S Dadeland Boulevard, Suite 1500. Miami Fl. 33156 United States

305-560-5337

info@stemcellsgroup.com

STAY CONNECTED

Get the latest news, updates, and promotions. Follow us on our social networks.

Certification issued by ISSCA

TOP